Author:
Loong Herbert H.,Wong Carlos K. H.,Leung Linda Kam Suet,Dhankhar Praveen,Insinga Ralph P.,Chandwani Sheenu,Hsu Danny C.,Lee Mary Y. K.,Huang Min,Pellissier James,Rai Akanksha,Achra Monika,Tan Seng Chuen
Funder
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Health Policy,Pharmacology
Reference46 articles.
1. Le Chevalier T. Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going? Ann Oncol. 2010;21(suppl_7):vii196–8.
2. Estimated cancer incidence, mortality and prevelance worldwide in 2012—lung cancer: GLOBOCAN. 2012.
http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
. Accessed 17 Nov 2017.
3. Hong Kong Cancer Registry: Hong Kong Hospital Authority.
http://www3.ha.org.hk/cancereg/
. Accessed 20 Nov 2017.
4. Lung Cancer. The Government of Hong Kong Special Administrative Region.
https://www.chp.gov.hk/en/healthtopics/content/25/49.html
. Accessed 20 Nov 2017.
5. What are the key statistics about lung cancer?
https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/key-statistics.html
. Accessed 20 Nov 2017.
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献